Diabetic
enteropathy (DE) is a diabetic complication and affects
the quality of life for which there are limited therapies. In this
study, db/db mice were administered
with a basic fibroblast growth factor (bFGF) to explore its therapeutic
effect on the intestine. 1H NMR-based metabolomics was
applied to investigate the metabolic pattern. H&E and PAS staining
were used to observe the morphological phenotypes related to intestinal
barrier function. Tight junction proteins such as Zo-1 and Occluding
were successively tested by immunofluorescence and real-time PCR.
We found that bFGF treatment significantly restored intestinal barrier
function. In addition, the administration of bFGF decreased the levels
of inflammatory cytokines in the cecum. Metabolomic results show that
bFGF remodeled metabolic phenotypes of the colon, cecum, and small
intestine in db/db mice, including
energy metabolism, short chain fatty acid metabolism, amino acid metabolism,
and choline metabolism. Hence, this study indicates that the bFGF
has a protective effect in diabetic bowel disease by restoring intestinal
barrier function, reducing inflammatory infiltration, and remodeling
metabolic function.